Table 9.
Anticancer studies of synthetic icetexanes reported by Deng and coworkers.
| IC50 (μM)[a] | HCT-116 | COLO-205 | Caco-2 |
|---|---|---|---|
| 36 | >20.87 | >20.87 | 13.71±1.36 |
| 29 | 18.77±1.39 | 11.15±1.07 | 3.07±1.52 |
| 54 | 2.93±1.08 | 3.18±0.95 | 2.71±1.10 |
| 55 | 13.33±1.57 | 10.42±1.38 | 3.86±0.98 |
| 56 | >20.23 | >20.23 | >20.23 |
| 58 | 10.58±2.01 | 7.81±1.74 | 7.20±1.56 |
| 190 | 18.55±2.33 | 18.52±2.52 | 10.42±2.64 |
| 191 | 11.07±1.92 | 7.52±1.19 | 13.81±1.82 |
| 193 | 2.70±0.73 | 3.39±1.45 | 2.69±1.08 |
| 5-FU [b] | 7.38 + 0.83 | 5.29±0.32 | 7.77±1.24 |
5-Fluorouracil (5-FU): positive control.
An average of three determinations.